Eli Lilly has confirmed it will expand its collaboration with data company Evidation, though terms of the agreement were not revealed. The partnership will see the former’s researchers and scientists utilise the latter’s data platform to record and understand patients' health. In a statement, Eli Lilly said that “Evidation is an innovative partner in our efforts to improve patient care through advanced health information.” The pharmaceutical firm’s scientists want to process information obtained via Evidation’s algorithms for deploying in clinical studies, or to build their own predictive models. Using techniques such as machine learning, artificial intelligence (AI) and state of the art data analysis, e-Therapeutics creates and analyses network models of disease to identify likely proteins that could be disrupted to treat diseases. This will ultimately be transformed into understanding better ways of monitoring and treating diseases.
Eli Lilly has confirmed it will expand its collaboration with data company Evidation, though terms of the agreement were not revealed. The partnership will see the former’s researchers and scientists utilise the latter’s data platform to record and understand patients' health. In a statement, Eli Lilly said that “Evidation is an innovative partner in our efforts to improve patient care through advanced health information.” The pharmaceutical firm’s scientists want to process information obtained via Evidation’s algorithms for deploying in clinical studies, or to build their own predictive models. This will ultimately be transformed into understanding better ways of monitoring and treating diseases.